LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 116

Search options

  1. Book ; Online: Chapter Linear regression pathmox segmentation tree: the case of visitors' satisfaction to attend a Spanish football match at the stadium

    Davino, Cristina / LAMBERTI, GIUSEPPE

    (Proceedings e report)

    2021  

    Series title Proceedings e report
    Keywords pathmox ; linear regression ; segmentation tree ; decision making ; heterogeneity ; visitors satisfaction
    Language 0|e
    Size 1 electronic resource (4 pages)
    Publisher Firenze University Press
    Publishing place Florence
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021614661
    ISBN 9788855184618 ; 885518461X
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Article: Neuroendocrine Tumors: Challenges and Future Perspectives.

    Lamberti, Giuseppe / La Salvia, Anna

    Journal of clinical medicine

    2022  Volume 11, Issue 15

    Abstract: The awareness and interest of the scientific community towards Neuroendocrine tumors (NETs) has progressively increased in the last few decades [ ... ]. ...

    Abstract The awareness and interest of the scientific community towards Neuroendocrine tumors (NETs) has progressively increased in the last few decades [...].
    Language English
    Publishing date 2022-07-27
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm11154351
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1-2 cm.

    Lamberti, Giuseppe / Andrini, Elisa / Ricci, Claudio / Campana, Davide

    The Lancet. Oncology

    2023  Volume 24, Issue 5, Page(s) e187

    MeSH term(s) Humans ; Neuroendocrine Tumors/surgery ; Neuroendocrine Tumors/pathology ; Appendiceal Neoplasms/surgery ; Appendiceal Neoplasms/pathology ; Colectomy/adverse effects ; Patients ; Appendectomy/adverse effects ; Retrospective Studies
    Language English
    Publishing date 2023-05-05
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(23)00059-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: An Update on Appendiceal Neuroendocrine Tumors.

    Andrini, Elisa / Lamberti, Giuseppe / Alberici, Laura / Ricci, Claudio / Campana, Davide

    Current treatment options in oncology

    2023  Volume 24, Issue 7, Page(s) 742–756

    Abstract: The mainstay of appendiceal neuroendocrine neoplasm (aNEN) treatment is surgery, based on simple appendectomy or right-sided hemicolectomy with lymphadenectomy (RHC). The majority of aNENs are adequately treated with appendectomy, but current guidelines ... ...

    Abstract The mainstay of appendiceal neuroendocrine neoplasm (aNEN) treatment is surgery, based on simple appendectomy or right-sided hemicolectomy with lymphadenectomy (RHC). The majority of aNENs are adequately treated with appendectomy, but current guidelines have poor accuracy in terms of selecting patients requiring RHC, especially in aNENs 1-2 cm in size. Simple appendectomy is curative for appendiceal NETs (G1-G2) < 1 cm (if the resection status is R0), whereas RHC with lymph node dissection is recommended in tumors ≥ 2 cm in diameter, based on the high risk of nodal metastases in these cases. The clinical management of aNENs 1-2 cm in size is more controversial because lymph node or distant metastases are uncommon but possible. In our opinion, patients with tumor size > 15 mm or with grading G2 (according to WHO 2010) and/or lympho-vascular invasion should be referred for radicalization with RHC. However, decision-making in these cases should include discussion within a multidisciplinary tumor board at referral centers with the aim of offering each patient a tailored treatment, also considering that relatively young patients with long-life expectancy represent the majority of cases.
    MeSH term(s) Humans ; Neuroendocrine Tumors/diagnosis ; Neuroendocrine Tumors/surgery ; Appendiceal Neoplasms/diagnosis ; Appendiceal Neoplasms/surgery ; Appendectomy ; Lymph Nodes/pathology ; Retrospective Studies
    Language English
    Publishing date 2023-05-04
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057351-0
    ISSN 1534-6277 ; 1527-2729
    ISSN (online) 1534-6277
    ISSN 1527-2729
    DOI 10.1007/s11864-023-01093-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Novel therapeutic strategies for recurrent SCLC.

    Moliner, Laura / Zhang, Bingnan / Lamberti, Giuseppe / Ardizzoni, Andrea / Byers, Lauren A / Califano, Raffaele

    Critical reviews in oncology/hematology

    2023  Volume 186, Page(s) 104017

    Abstract: Therapeutic options for patients with relapsed SCLC are limited, and the prognosis in this setting remains poor. While clinical outcomes for frontline treatment have modestly improved with the introduction of immunotherapy, treatment in the second-line ... ...

    Abstract Therapeutic options for patients with relapsed SCLC are limited, and the prognosis in this setting remains poor. While clinical outcomes for frontline treatment have modestly improved with the introduction of immunotherapy, treatment in the second-line setting persists almost unchanged. In this review, current treatment options and recent advances in molecular biology are described. Emerging therapeutic options in this setting, and potential strategies to improve clinical outcomes of these patients are also addressed.
    MeSH term(s) Humans ; Lung Neoplasms/therapy ; Lung Neoplasms/drug therapy ; Neoplasm Recurrence, Local/drug therapy ; Small Cell Lung Carcinoma/drug therapy ; Immunotherapy ; Prognosis
    Language English
    Publishing date 2023-05-05
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 605680-5
    ISSN 1879-0461 ; 0737-9587 ; 1040-8428
    ISSN (online) 1879-0461
    ISSN 0737-9587 ; 1040-8428
    DOI 10.1016/j.critrevonc.2023.104017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Tackling hurdles in front of young clinical investigators in oncology - Results from an international survey.

    Vasileva-Slaveva, Mariela / Morales-Espinosa, Daniela / Puccini, Alberto / Meissner, Magdalena / Milic, Marina / Lamberti, Giuseppe / Altena, Renske

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

    2024  Volume 50, Issue 6, Page(s) 108031

    Abstract: Introduction: Cancer is a leading cause of morbidity and mortality worldwide, and coordinated research efforts are vital to improve global outcomes. Clinical or translational research is usually planned, coordinated and executed by clinical researchers. ...

    Abstract Introduction: Cancer is a leading cause of morbidity and mortality worldwide, and coordinated research efforts are vital to improve global outcomes. Clinical or translational research is usually planned, coordinated and executed by clinical researchers. With this survey we aimed to identify the main hurdles in front of young clinical investigators in oncology.
    Methods and materials: An anonymized survey was distributed using social media between April and November 2022. Target population were health-care professionals in the field of oncology - physicians, nurses and researchers. We divided participants according to working experience (<40 vs. >40 years of age) and country of practice (Europeans vs. non-Europeans).
    Results: We received 121 responses from participants practicing in 36 countries. Eighty-seven (72%) of the participants were under 40 years. Eighty-nine (74%) were from European countries and thirty-two (26%) were from non-European. Experienced and European professionals were more likely to be involved in all different aspects of clinical trials. The main source of funding - independently of geographic location - were industry grants. Investigators out of Europe have less participation in international grants. Over 50% of participants dedicate time for clinical research from their personal time and are not paid for it. Almost 50% of investigators don't have access to an experienced mentor in their institution.
    Conclusion: The majority of respondents to our survey are active clinical researchers. Our data indicate that access to education and training as well as possibilities for appropriate networking, and specifically lack of mentorship, are key limiting factors in developing clinical research by healthcare professionals.
    Language English
    Publishing date 2024-03-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 632519-1
    ISSN 1532-2157 ; 0748-7983
    ISSN (online) 1532-2157
    ISSN 0748-7983
    DOI 10.1016/j.ejso.2024.108031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option.

    Ricciuti, Biagio / Lamberti, Giuseppe / Roila, Fausto / Metro, Giulio

    Translational lung cancer research

    2020  Volume 8, Issue Suppl 4, Page(s) S378–S382

    Language English
    Publishing date 2020-01-30
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2754335-3
    ISSN 2226-4477 ; 2218-6751
    ISSN (online) 2226-4477
    ISSN 2218-6751
    DOI 10.21037/tlcr.2019.04.15
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Should we lose hope in adjuvant therapy for neuroendocrine tumors?-In response to: Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.

    Lamberti, Giuseppe / Manuzzi, Lisa / Maggio, Ilaria / Campana, Davide

    Journal of surgical oncology

    2020  Volume 122, Issue 3, Page(s) 570–571

    MeSH term(s) Humans ; Intestinal Neoplasms ; Neuroendocrine Tumors ; Pancreatic Neoplasms ; Stomach Neoplasms
    Language English
    Publishing date 2020-06-10
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 82063-5
    ISSN 1096-9098 ; 0022-4790
    ISSN (online) 1096-9098
    ISSN 0022-4790
    DOI 10.1002/jso.25969
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Non-small-cell lung cancer: how to manage

    Andrini, Elisa / Mosca, Mirta / Galvani, Linda / Sperandi, Francesca / Ricciuti, Biagio / Metro, Giulio / Lamberti, Giuseppe

    Drugs in context

    2022  Volume 11

    Abstract: Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). ...

    Abstract Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC).
    Language English
    Publishing date 2022-07-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2719560-0
    ISSN 1740-4398 ; 1745-1981
    ISSN (online) 1740-4398
    ISSN 1745-1981
    DOI 10.7573/dic.2022-1-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities.

    De Giglio, Andrea / Orlando, Valentina / Andrini, Elisa / Ricciuti, Biagio / Lamberti, Giuseppe / Chiari, Rita

    Tumori

    2022  Volume 109, Issue 1, Page(s) 105–111

    Abstract: Background: Molecular testing is crucial for the implementation of personalized therapy in patients with lung cancer. Whether routine biomarker testing and access to personalized therapies are limited in some Italian regions is unclear.: Patients and ... ...

    Abstract Background: Molecular testing is crucial for the implementation of personalized therapy in patients with lung cancer. Whether routine biomarker testing and access to personalized therapies are limited in some Italian regions is unclear.
    Patients and methods: We conducted a national cross-sectional survey between April and June 2019 among Italian oncologists to determine differences in biomarker testing and access to personalized therapies for lung cancer.
    Results: Based on GIMBE report n. 3/2018, 32 respondents (37.6%) were defined as belonging to budget deficit regions (BDRs) while 53 (62.4%) were from balanced/positive budget regions (BPRs). Diagnostic assays for EGFR/ALK/ROS1 and PD-L1 were reported to be available in 47/53 (88.7%) and 22/32 (68.85%) centers from BPRs and BDRs, respectively (p=0.04).Liquid biopsy accessibility was wider in BPRs than in BDRs (75.5% (40/53) vs. 50% (16/32), respectively; p=0.03). 84/85 (98.8%) oncologists reported that ⩾75% of eligible patients received first-line targeted therapies. Reason for not administering first-line targeted therapies was defined as clinically-unrelated (molecular testing not available or incomplete, pharmacoeconomic issues) by 25/42 (59.5%) of respondents from BPRs and 21/26 (80.6%) from BDRs (p=0.12). Reason for not administering first-line pembrolizumab was defined as clinically-unrelated by 8/43 (18.6%) of respondents from BPRs and 10/22 (45.4%) from BDRs (p=0.039).
    Conclusion: Disparities in access to diagnostic assay and first line immunotherapy exist between BPRs and BDRs.
    MeSH term(s) Humans ; Protein-Tyrosine Kinases ; Cross-Sectional Studies ; Proto-Oncogene Proteins ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Lung Neoplasms/drug therapy ; Lung Neoplasms/epidemiology ; Oncologists
    Chemical Substances Protein-Tyrosine Kinases (EC 2.7.10.1) ; Proto-Oncogene Proteins
    Language English
    Publishing date 2022-02-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 280962-x
    ISSN 2038-2529 ; 0300-8916
    ISSN (online) 2038-2529
    ISSN 0300-8916
    DOI 10.1177/03008916211069412
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top